<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6101">
  <stage>Registered</stage>
  <submitdate>5/07/2016</submitdate>
  <approvaldate>5/07/2016</approvaldate>
  <nctid>NCT02826018</nctid>
  <trial_identification>
    <studytitle>A Study of ALN-HBV in Healthy Adult Volunteers and Non-cirrhotic Patients With Chronic Hepatitis B Virus (HBV) Infection</studytitle>
    <scientifictitle>A Phase 1/2, Randomized, Single-Blind, Placebo-Controlled, Single-Ascending and Multiple-Ascending Dose, Safety, Tolerability, Pharmacokinetics, and Antiviral Efficacy Study of Subcutaneously Administered ALN-HBV in Healthy Adult Subjects and Non-cirrhotic Patients With Chronic Hepatitis B Virus (HBV) Infection</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>ALN-HBV-001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hepatitis B</healthcondition>
    <healthcondition>Chronic Hepatitis B</healthcondition>
    <healthcondition>Hepatitis B, Chronic</healthcondition>
    <healthcondition>Hepatitis B Infection</healthcondition>
    <healthcondition>HBV</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Studies of infection and infectious agents</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Sexually transmitted infections</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - ALN-HBV
Treatment: drugs - Sterile Normal Saline (0.9% NaCl)

Active Comparator: ALN-HBV - 

Placebo Comparator: Sterile Normal Saline (0.9% NaCl) - 


Treatment: drugs: ALN-HBV
Ascending doses of ALN-HBV by subcutaneous (sc) injection

Treatment: drugs: Sterile Normal Saline (0.9% NaCl)
Calculated volume to match active comparator

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Proportion of subjects experiencing adverse events</outcome>
      <timepoint>Part A (SAD phase): through Day 29; Part B (SAD phase): through Day 85; Part C (MAD phase): through Day 176</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Profile of Pharmacokinetics (PK) of ALN-HBV - Maximum plasma concentration (Cmax)</outcome>
      <timepoint>Part A (SAD phase): Day 1; Part B (SAD phase): Day 1; Part C (MAD phase): Days 1 and 85</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Profile of Pharmacokinetics (PK) of ALN-HBV - Elimination half-life (t1/2)</outcome>
      <timepoint>Part A (SAD phase): Day 1; Part B (SAD phase): Day 1; Part C (MAD phase): Days 1 and 85</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Profile of Pharmacokinetics (PK) of ALN-HBV - Area under the concentration-time curve (AUC)</outcome>
      <timepoint>Part A (SAD phase): Day 1; Part B (SAD phase): Day 1; Part C (MAD phase): Days 1 and 85</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in quantitative hepatitis B surface antigen (HBsAg) levels - Change in HBsAg levels from baseline</outcome>
      <timepoint>Part B (SAD phase): baseline through Day 85; Part C (MAD phase): baseline through Day 176</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>All subjects:

          -  18 to 65 years inclusive

          -  Women of child-bearing potential must have a negative pregnancy test, cannot be breast
             feeding, and must be willing to use a highly effective method of contraception

          -  Agrees not to donate blood during the duration of the study

          -  Willing to comply with the study requirements and to provide written informed consent

        Additional inclusion criteria for patients with HBV infection:

          -  Body mass index (BMI) =18.0 kg/m2

          -  Must be on a stable regimen of entecavir or tenofovir</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>All subjects:

          -  Any uncontrolled or serious disease, or any medical or surgical condition, that may
             either interfere with participation in the clinical study, and/or put the subject at
             significant risk

          -  Subjects with a history of serious mental illness

          -  Active infection with human immunodeficiency virus (HIV) infection, hepatitis A virus
             (HAV), or hepatitis C virus (HCV) infection and/or a history of delta virus hepatitis

          -  Known hypersensitivity or contraindication to any medication or history of allergic
             reaction to an oligonucleotide or N-acetylgalactosamine (GalNAc)

        Additional exclusion criteria for healthy volunteers:

          -  Evidence of liver disease</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1/Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>112</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/04/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA,VIC</recruitmentstate>
    <hospital>Clinical Trial Site - Adelaide</hospital>
    <hospital>Clinical Trial Site - Fitzroy</hospital>
    <hospital>Clinical Trial Site - Parkville</hospital>
    <postcode> - Adelaide</postcode>
    <postcode> - Fitzroy</postcode>
    <postcode> - Parkville</postcode>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Hong Kong</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state>Singapore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Alnylam Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine the safety, tolerability and pharmacokinetics of
      ALN-HBV in healthy adult volunteers and patients with chronic hepatitis B virus (HBV)
      infection. In addition, the study will assess antiviral efficacy of ALN-HBV in patients with
      HBV.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02826018</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Stephen Huang, MD</name>
      <address>Alnylam Pharmaceuticals</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>